Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Poster Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV Certara2019年6月24日
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper がん免疫療法の創薬と開発をQSPで最適化 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…Certara2019年6月19日
Pirana Modeling Workbench Brochure Pirana モデリングワークベンチ Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…Certara2019年5月28日
Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Certara2019年5月2日
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Certara2019年4月22日
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Certara2019年4月22日
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Certara2019年4月22日
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Certara2019年4月22日
How to Perform IVIVC for Extremely Long Acting Drugs On-Demand Webinar How to Perform IVIVC for Extremely Long Acting Drugs Watch this webinar to learn how to use in vitro and in vivo models to…Certara2019年2月22日
Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Poster Automated Average Bioequivalence Analysis with Additional Metrics and Statistics to Meet the FDA Guidance on Methylphenidate Hydrochloride Using Phoenix WinNonlin Certara2018年11月4日